Chemo-Immunotherapy: A New Trend in Cancer Treatment
Cancers · 25.05.2023 · 15 (11) · 2912
DOI: 10.3390/cancers15112912 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.05.2023. Verfasst von Christian Sordo-Bahamonde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, Spain. Die Arbeit wurde bisher 180-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Cáncer, Fundación Galbán.
Abstract (Originalsprache)
Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, Spain.
- Instituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, Spain.
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
- Department of Hematology, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
- Department of Otolaryngology-Head and Neck Surgery, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Christian Sordo-Bahamonde, Ana P Gonzalez-Rodriguez, Alejandra Martínez-Pérez, Juana M García-Pedrero, Segundo Gonzalez
Förderung
- Instituto de Salud Carlos III
- Centro de Investigación Biomédica en Red de Cáncer
- Fundación Galbán
- Ayudas a Grupos PCTI Principado de Asturias
- Spanish grant of Instituto de Salud Carlos III
- CIBERONC
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA)
- Fundación Bancaria Cajastur
Zitieren
APA
Sordo-Bahamonde, C., Lorenzo-Herrero, S., Gonzalez-Rodriguez, A. P., Martínez-Pérez, A., Rodrigo, J. P., García-Pedrero, J. M., & Gonzalez, S. (2023). Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers, 15(11), 2912. https://doi.org/10.3390/cancers15112912
Vancouver
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Martínez-Pérez A, Rodrigo JP, García-Pedrero JM, et al. Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers. 2023;15(11):2912. doi:10.3390/cancers15112912
BibTeX
@article{SordoBahamonde2023,
author = {Sordo-Bahamonde, Christian and Lorenzo-Herrero, Seila and Gonzalez-Rodriguez, Ana P and Martínez-Pérez, Alejandra and Rodrigo, Juan P and García-Pedrero, Juana M and Gonzalez, Segundo},
title = {Chemo-Immunotherapy: A New Trend in Cancer Treatment},
journal = {Cancers},
year = {2023},
volume = {15},
number = {11},
pages = {2912},
doi = {10.3390/cancers15112912}
}
EUVIMED